在慢性阻塞性肺病中需要吸入固酶抑制剂
Mario Cazzola1, Luigino Calzetta2, Paola Rogliani1
1Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Expert review of clinical pharmacology
|December 3, 2024
概括
与口服版本相比,吸入型固醇酶 (PDE) 抑制剂为COPD提供了更好的治疗选择. 研究重点是提米拉斯和恩西芬,以改善肺功能和生活质量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 药物运输 药物运输 药物运输
背景情况:
- 固酶 (PDE) 抑制剂正在作为COPD治疗的细胞内标被探索.
- 目前用于COPD的口服PDE4抑制剂具有狭窄的治疗指数,限制了它们的使用.
- 吸入途径为增强PDE抑制剂治疗提供了一个有希望的替代方案.
研究的目的:
- 审查吸入PDE4抑制剂的开发和治疗潜力,特别是tamiilast和ensifentrine.
- 评估吸入PDE抑制剂在COPD管理中的优势.
- 讨论COPD患者吸入PDE抑制剂所观察到的临床益处.
主要方法:
- 关于吸入PDE4抑制剂的现有文献的审查.
- 专注于坦米拉斯和恩西芬,包括恩西芬作为双重PDE3/PDE4抑制剂.
- 对有关疗效和安全的临床数据的分析.
主要成果:
- 吸入的坦米拉斯和恩西芬已经证明了肺功能的改善.
- 这些药物已经显示出降低COPD恶化的潜力.
- 在使用吸入PDE抑制剂的COPD患者中报告了改善生活质量的情况.
结论:
- 吸入PDE4抑制剂是改善COPD治疗治疗指数的可行策略.
- 需要进一步的研究,以确定从这些疗法中获益最多的特定COPD患者群体.
- 双重PDE3/PDE4抑制与单独抑制PDE4的比较好处需要进一步研究.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
01:23Inhaled Medications
244
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
244
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160
01:26COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K